X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of PM359, which involves the use of prime editing technology to modify autologous hematopoietic stem cells ex vivo. This blood-targeting therapy is being developed as a potential treatment for chronic granulomatous disease.
Lead Product(s): PM359
Therapeutic Area: Genetic Disease Product Name: PM359
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $161.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 20, 2024
Details:
The net proceeds will be used for the development of PM359, which involves the use of prime editing technology to modify autologous hematopoietic stem cells ex vivo. This blood-targeting therapy is being developed as a potential treatment for chronic granulomatous disease.
Lead Product(s): PM359
Therapeutic Area: Genetic Disease Product Name: PM359
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 14, 2024
Details:
The net proceeds will be used to support the development of curative therapies by using Prime Editing to correct CFTR mutations at the natural genetic locus, for the treatment of Cystic Fibrosis (CF).
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Funding January 25, 2024
Details:
Under the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, to develop a new class of differentiated, one-time, potentially curative genetic therapies.
Lead Product(s): Genetic Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: MaxCyte
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 01, 2023
Details:
Under the collaboration, Prime Medicine will receive an exclusive option to license Cimeio’s cell shielding technology for CD117-shielded HSC transplant, as well as in vivo editing of CD117-shielded HSCs, for genetic diseases.
Lead Product(s): CD117-shielded Cell
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cimeio Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 22, 2023
Details:
Company expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 24, 2022
Details:
Company expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
